MarketCap
Facebook
X
Telegram
Cardiovascular Systems EBITDA | CSII
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.1 M | -8.84 M | -23.8 M | 2.32 M | 5.96 M | 2.38 M | -52.4 M | -30.5 M | -32.2 M | -22.3 M | -14.4 M | -8.76 M | -22.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.96 M | -52.4 M | -18.3 M |
Quarterly EBITDA Cardiovascular Systems
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.73 M | -10 M | -8.18 M | -6.81 M | -6.66 M | -7.16 M | -8.21 M | -7.16 M | -3.42 M | -5.34 M | 587 K | -933 K | -1.88 M | -5.19 M | -3.04 M | 2.89 M | 1.96 M | -2.17 M | 439 K | 3.42 M | 1.71 M | -758 K | -275 K | 1.17 M | 3.02 M | -910 K | 1.08 M | -20 M | -13.3 M | -12.3 M | -15.1 M | -9.25 M | -4.5 M | -7.82 M | -5.25 M | -9.46 M | -7.39 M | -6.82 M | -7.5 M | -5.27 M | -5.02 M | -5.18 M | -5.12 M | -3.68 M | -3.66 M | -3.1 M | -3.66 M | -3.06 M | -3.66 M | -3.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.42 M | -20 M | -4.64 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
LivaNova PLC
LIVN
|
228 M | $ 76.43 | 1.81 % | $ 4.17 B |  Britain |
 |
LENSAR
LNSR
|
-21 M | $ 6.67 | 0.59 % | $ 79.8 M |  USA |
 |
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.88 | 2.73 % | $ 76.5 M | USA |
 |
Medtronic PLC
MDT
|
9.42 B | $ 87.97 | 1.88 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
78.8 M | $ 4.55 | 0.54 % | $ 672 M | USA |
 |
Myomo
MYO
|
-13.5 M | $ 1.67 | 2.45 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-77 M | $ 0.64 | 1.15 % | $ 41.5 M |  Israel |
 |
InspireMD
NSPR
|
426 M | $ 0.58 | 1.64 % | $ 37.3 M | Israel |
 |
Orthofix Medical
OFIX
|
-4.11 M | $ 9.5 | 4.51 % | $ 376 M |  Curacao |
 |
Outset Medical
OM
|
-62.4 M | $ 4.1 | 3.54 % | $ 62.4 K | USA |
 |
PAVmed
PAVM
|
-21.7 M | $ 2.66 | 4.36 % | $ 1.78 M | USA |
 |
Penumbra
PEN
|
207 M | $ 317.11 | 0.07 % | $ 12.3 B | USA |
 |
Insulet Corporation
PODD
|
564 M | $ 135.62 | 2.98 % | $ 9.54 B | USA |
 |
Profound Medical Corp.
PROF
|
-40.9 M | $ 6.03 | 3.25 % | $ 182 M |  Canada |
 |
Quanterix Corporation
QTRX
|
-110 M | $ 3.81 | 4.67 % | $ 162 M | USA |
 |
AVITA Medical
RCEL
|
-40.2 M | $ 13.25 | 4.17 % | $ 369 M |  Australia |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 2.18 | 1.05 % | $ 6.05 M | USA |
 |
Smith & Nephew plc
SNN
|
1.37 B | $ 26.92 | 1.87 % | $ 23.3 B | Britain |
 |
Sensus Healthcare
SRTS
|
-9.91 M | $ 2.92 | 0.34 % | $ 47.7 M | USA |
 |
Stryker Corporation
SYK
|
6.46 B | $ 285.22 | 3.54 % | $ 109 B | USA |
 |
Tactile Systems Technology
TCMD
|
35.9 M | $ 22.47 | 1.67 % | $ 514 M | USA |
 |
TELA Bio
TELA
|
-33.1 M | $ 1.14 | 0.88 % | $ 53.5 M | USA |
 |
TransMedics Group
TMDX
|
136 M | $ 82.99 | 4.0 % | $ 2.82 B | USA |
 |
Tandem Diabetes Care
TNDM
|
26 M | $ 16.52 | 0.12 % | $ 1.12 B | USA |
 |
Viemed Healthcare
VMD
|
51.6 M | $ 9.24 | 1.2 % | $ 359 M | USA |
 |
Varex Imaging Corporation
VREX
|
-4.6 M | $ 18.45 | 0.14 % | $ 764 M | USA |
 |
Vivos Therapeutics
VVOS
|
-18.6 M | $ 0.15 | 1.52 % | $ 1.54 M | USA |
 |
Beyond Air
XAIR
|
-25.9 M | $ 2.84 | 0.71 % | $ 23.6 B | USA |
 |
Xtant Medical Holdings
XTNT
|
12.5 M | $ 0.33 | 0.09 % | $ 46 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.19 B | $ 91.57 | 3.72 % | $ 18.1 B | USA |
 |
Nemaura Medical
NMRD
|
-9.15 M | - | -17.8 % | $ 2.74 M | Britain |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | Canada |
 |
Sientra
SIEN
|
-62.4 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-56.6 M | - | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
-76.3 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
169 M | - | - | $ 12.3 B | USA |
 |
Titan Medical
TMDI
|
-31 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Natus Medical Incorporated
NTUS
|
51.9 M | - | 1.94 % | $ 1.05 B | USA |
 |
Inari Medical
NARI
|
-7.14 M | - | - | $ 4.23 B | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-13.6 M | - | - | $ 3.31 B | USA |
 |
ThermoGenesis Holdings
THMO
|
-7.46 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
-66 M | - | 3.55 % | $ 7.96 M | USA |
 |
Viveve Medical
VIVE
|
-20.4 M | - | -15.35 % | $ 1.71 M | USA |
 |
ViewRay
VRAY
|
-102 M | - | 1.54 % | $ 468 M | USA |
 |
SmileDirectClub
SDC
|
-188 M | - | -53.45 % | $ 9.71 M | USA |
 |
Acutus Medical
AFIB
|
240 K | - | -26.83 % | $ 2.62 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |